Serious allergic reactions to administered chimeric MABs now on the market [ie Erbitux] are acknowledged to be about 5%. It appears that even patients with pre-existing "mouse anti-bodies" [most of the world's population] may have an average 44 day window of treatment before incidence of reactions spikes. This is my own conclusion from skimming the data.
Market Data 
Markets 
AI
